her2 -低表达与her2 -零表达非特殊型浸润性乳腺癌临床病理特征及预后意义的比较分析

Yuanyuan Chen, Xin Ye, Jie Wang, Baosan Han
{"title":"her2 -低表达与her2 -零表达非特殊型浸润性乳腺癌临床病理特征及预后意义的比较分析","authors":"Yuanyuan Chen, Xin Ye, Jie Wang, Baosan Han","doi":"10.4103/jcrt.jcrt_277_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.</p><p><strong>Methods: </strong>Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.</p><p><strong>Results: </strong>Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).</p><p><strong>Conclusion: </strong>The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"425-434"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative analysis of the clinicopathological features and prognostic implications of invasive breast carcinoma of nonspecial type exhibiting HER2-low and HER2-zero expressions.\",\"authors\":\"Yuanyuan Chen, Xin Ye, Jie Wang, Baosan Han\",\"doi\":\"10.4103/jcrt.jcrt_277_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.</p><p><strong>Methods: </strong>Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.</p><p><strong>Results: </strong>Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).</p><p><strong>Conclusion: </strong>The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.</p>\",\"PeriodicalId\":94070,\"journal\":{\"name\":\"Journal of cancer research and therapeutics\",\"volume\":\"21 2\",\"pages\":\"425-434\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrt.jcrt_277_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_277_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:回顾性研究HER2低表达和零表达的非特殊型浸润性乳腺癌(IBC-NST)的临床病理特征、治疗方法、预后差异及影响因素。方法:从2009年7月至2019年12月上海交通大学乳腺癌数据库中获取HER2低表达和零表达的IBC-NST患者的临床数据。采用Kaplan-Meier法、log-rank检验和Cox回归分析。结果:2071例IBC-NST患者中,1618例(78.1%)HER2低表达,453例(21.9%)HER2零表达。在her2 - 0组中,年龄在40岁以下的患者比例更高,Ki67 >占20%,肿瘤分级为III级。在her2低组中,雌激素受体阳性、孕激素受体阳性、激素受体(HR)阳性以及接受内分泌治疗的比例较高。两组间乳腺癌无癌间期(BCFI)和总生存期(OS)相似。hr阳性亚组的临床病理特征、治疗方式、BCFI、OS差异无统计学意义。在hr阴性亚组中,her2低组中40岁以上患者和绝经后患者的比例更高。多因素分析显示,无论HER2状态如何,淋巴结分期(N2-N3)是BCFI和OS的独立危险因素。同时,HER2-low是hr阴性亚组BCFI的独立危险因素(风险比为1.781,95%可信区间为1.061 ~ 2.989,P = 0.029)。结论:低her2型IBC-NST的临床生物学特征可能受HR状态的影响。在相同HR状态下,her2 -低和her2 -零IBC-NST的临床病理特征和预后具有可比性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparative analysis of the clinicopathological features and prognostic implications of invasive breast carcinoma of nonspecial type exhibiting HER2-low and HER2-zero expressions.

Purpose: This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.

Methods: Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.

Results: Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).

Conclusion: The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信